Human bispecific EGFRvIII antibody and CD3 engaging molecules

US9676858B2 · kind B2 · utility

Assignees

• Duke University · US
• The United States of America as Represented by the Secretary Department of Health and Human Services (NIH) · US

Inventors

• Darell Bigner · Mebane, US
• Chien-Tsun Kuan · Cary, US
• John H. Sampson · Durham, US
• Bryan Choi · Boston, US
• Ira H. Pastan · Potomac, US
• Patrick C. Gedeon · Durham, US

Key dates

• Filing date: Jun 7, 2013
• Grant date: Jun 13, 2017
• Expiry date: Jul 16, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These may be used as therapeutic agents.